Category Finance

WTO TRIPS Council: For Some, IP-Intensive Industries Are Engine Of Economy. For Others, IP Alone Is Not Sufficient

The World Trade Organization committee on intellectual property met this week and gave an opportunity to WTO members to discuss the value of intellectual property for micro, small and medium sized enterprises (MSMEs), and its importance for IP-intensive industries. Several members, such as the European Union on behalf of its members presented data to illustrate the importance of IP for MSMEs. Meanwhile, India and South Africa remarked that IP is only one factor to promote innovation, but are not a sufficient ingredient.

Wellcome Trust Report Recommends UK-EU Agreement On Research & Innovation

The Wellcome Trust, the London-based biomedical research charity, has issued recommendations for improved scientific collaboration after Brexit, including to establish a formal agreement on research and innovation. This includes continued leadership by the UK on open research, and might include expanding the UK patent box scheme, it says.

German Court To Hear Unified Patent Court Challenge, As EPO Staff Questions Persist

The German Federal Constitutional Court has agreed to take up a challenge that could potentially derail the Unified Patent Court (UPC). The special - and opaque - procedure under the national constitution allows a single individual to claim constitutional breaches, said Hogan Lovells (Dusseldorf) patent litigator Clemens Plassmann. The lawsuit leaves the UPC in disarray at least until next year, he said.

Meanwhile, in the never-ending feud between European Patent Office (EPO) management and staff, President Benoȋt Battistelli was forced to back off from a planned rule change that would allow him to fire staff members “if the exigencies of the service require abolition of their post or a reduction in staff.”

Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices

Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it.

WHO Names High-Profile Commission On Non-Communicable Diseases

The World Health Organization today announced a new high-level commission of heads of state, ministers and other leaders in health and development to come up with "bold and innovative solutions" against non-communicable diseases such as heart and respiratory diseases, cancers and diabetes. The chairs of the commission include the presidents of Uruguay, Sri Lanka, and Finland, the Russian health minister, and a former minister of Pakistan who was a candidate for director general of the WHO. They are joined by nearly two dozen others, including corporate public figures Michael Bloomberg and Jack Ma.

Interview With Peter Vanderheyden, CEO Of Article One Partners

Article One Partners (AOP), the world leader in crowdsourced intellectual property research, is now into their 10th year. Intellectual Property Watch recently arranged an interview with Article One Partners CEO Peter Vanderheyden to get an update on how the company has evolved in response to the ever-changing IP landscape, and in light of their commitment to IP quality.

CARB-X Announces First Award Of 2018; Seeks Partners For Antibacterial Research

CARB-X, the private-public partnership for research on antimicrobial resistance, today announced its first award of 2018, nearly $2 million for the development of a new class of antibiotics. Meanwhile, the group has announced it is seeking to partner with accelerator organisations to build its pipeline of early development research projects. It also announced a study that called for a new global approach and greater financial incentives for antibiotic research.

Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t

The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue.